-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from 2020 to 2023.
- Elite Pharmaceuticals Inc /Nv/ Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2024 was $18.9M, a 33.4% increase year-over-year.
- Elite Pharmaceuticals Inc /Nv/ Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending September 30, 2024 was $71.2M, a 73.4% increase year-over-year.
- Elite Pharmaceuticals Inc /Nv/ annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $56.6M, a 65.8% increase from 2022.
- Elite Pharmaceuticals Inc /Nv/ annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $34.2M, a 5.87% increase from 2021.
- Elite Pharmaceuticals Inc /Nv/ annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $32.3M, a 27.1% increase from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Growth (%)